Wegovy and Other Weight Loss Drugs Linked to Serious Side Effects
Wegovy is part of a drug class known as glucagon like peptide 1 receptor agonists, which affect appetite, insulin signaling, and stomach emptying.
The same delayed gastric emptying that helps some patients eat less is central to current lawsuits alleging severe gastrointestinal problems involving the digestive tract.
Wegovy prescribing information states that the drug delays gastric emptying, has been associated with gastrointestinal adverse events that are sometimes severe, and is not recommended for patients with severe gastroparesis.
Researchers found that GLP-1 agonists used for weight loss were associated with increased risks of pancreatitis, gastroparesis, and bowel obstruction compared with bupropion-naltrexone, although that study should be understood as observational rather than definitive proof of causation.
Clinical trials and prescribing information also identify common gastrointestinal reactions such as nausea, vomiting, diarrhea, constipation, abdominal pain, bloating, and related symptoms.
Federal lawsuits allege that drug makers failed to adequately warn patients and physicians about the severity and persistence of these risks.
Serious injuries and symptoms discussed in Wegovy and GLP-1 litigation may include:
- Gastroparesis or delayed gastric emptying
- Stomach paralysis symptoms, including nausea, vomiting, bloating, abdominal pain, early fullness, and difficulty keeping food down
- Ileus or intestinal blockage
- Bowel obstruction or pseudo-obstruction
- Persistent vomiting and dehydration
- Malnutrition or inability to tolerate normal food intake
- Severe abdominal pain requiring emergency care or hospitalization
- Pancreatitis, which has been reported as a risk signal in GLP-1 research
- NAION-related vision loss, which should be evaluated separately from gastrointestinal injury claims
These allegations do not mean every patient who used Wegovy has a claim.
A potential lawsuit usually depends on prescription history, dose timing, symptom onset, diagnosis, medical testing, hospitalization, prior gastrointestinal history, and damages.
People with severe or persistent symptoms should seek medical care rather than stopping or changing medication without professional guidance.
TorHoerman Law can review whether the medical records and treatment timeline support a Wegovy or GLP-1 injury claim.
What Severe Health Complications are Alleged in Wegovy Lawsuits?
Wegovy lawsuits allege that semaglutide and other GLP 1 receptor agonists can cause or contribute to severe gastrointestinal injuries in some users, including gastroparesis, ileus, intestinal obstruction, persistent vomiting, dehydration, and malnutrition.
Gastroparesis occurs when the stomach muscles do not move food normally through the digestive tract, which can cause nausea, vomiting, bloating, abdominal pain, early fullness, and difficulty keeping food down.
Wegovy prescribing information states that the drug delays gastric emptying, has been associated with gastrointestinal adverse reactions that are sometimes severe, and is not recommended in patients with severe gastroparesis.
Researchers have reported an association between GLP-1 drugs used for weight loss and increased risk of gastroparesis, bowel obstruction, and pancreatitis, although the study was observational and does not by itself prove causation.
Plaintiffs allege that many patients were not adequately warned that delayed gastric emptying could become severe, prolonged, or medically disruptive.
Some recent safety reviews have also examined whether Wegovy linked risks may include NAION, a rare optic nerve condition that can cause sudden vision loss; in 2025, the European Medicines Agency concluded that NAION is a very rare side effect of semaglutide medicines.
The main federal Wegovy litigation remains focused on gastrointestinal injuries, while NAION-related allegations should be evaluated separately based on medical records, diagnosis, timing, and prescribing history.
Patients with persistent vomiting, severe abdominal pain, dehydration, inability to tolerate food, bowel-obstruction symptoms, or sudden vision changes should seek medical care promptly.
Is Wegovy Linked to Sudden Vision Loss?
Recent safety reviews have examined whether semaglutide medicines, including Wegovy, may be associated with non-arteritic anterior ischemic optic neuropathy, or NAION.
NAION involves reduced blood flow to the optic nerve and can cause sudden, painless vision loss in one eye.
In 2025, the European Medicines Agency recommended updating semaglutide product information to include NAION as a very rare side effect.
This issue should be evaluated separately from the gastrointestinal injury claims centralized in MDL No. 3094 because the medical evidence, injury pattern, and claim criteria may differ.
Wegovy users who experienced sudden vision changes or lost vision should seek medical care promptly and preserve prescription records, ophthalmology records, diagnostic testing, and treatment history.
Wegovy Lawsuit Overview
Wegovy lawsuits involve allegations that Novo Nordisk failed to adequately warn about serious gastrointestinal disorders linked to semaglutide use. Federal GLP-1 injury cases are centralized in MDL No. 3094 in the Eastern District of Pennsylvania and include claims involving Wegovy, Ozempic, Rybelsus, Trulicity, and Mounjaro.
Wegovy prescribing information states that the drug delays gastric emptying and has been associated with gastrointestinal adverse reactions that are sometimes severe.
Wegovy gastroparesis claims focus on whether delayed gastric emptying progressed into severe or persistent injury, including stomach paralysis, chronic vomiting, ileus, or bowel obstruction.
Scientific studies have reported associations between GLP-1 drugs used for weight loss and increased rates of gastroparesis, bowel obstruction, and pancreatitis, though each claim still depends on individual medical proof.
There is not a Wegovy class action lawsuit: each person’s claim remains tied to their prescription history, diagnosis, treatment course, and damages.
Vision-loss claims involving NAION are also being reviewed, but those injuries should be evaluated separately from the gastrointestinal claims in the federal MDL.
Current Wegovy lawsuit allegations may involve:
- Gastroparesis or delayed gastric emptying
- Intestinal obstruction or bowel obstruction
- Ileus
- Persistent vomiting
- Severe abdominal pain
- Dehydration or malnutrition
- Hospitalization or emergency treatment
- Failure to warn about severe gastrointestinal risks
- NAION-related sudden vision loss, when supported by medical records
What is the Average Wegovy Lawsuit Settlement Amount?
No Wegovy settlement has been reached, and there is no confirmed average settlement amount for Wegovy claims at this stage.
Lawyers involved in these cases estimate that GLP-1 lawsuit settlement amounts may range from $50,000 to over $700,000, depending on injury severity, medical evidence, and the impact on the person’s life.
These figures are projections, not guaranteed outcomes, and are based on how similar dangerous drug lawsuits have been valued in prior mass tort litigation.
Wegovy claims involving hospitalization, long-term gastroparesis, intestinal obstruction, persistent vomiting, malnutrition, future medical care, or permanent impairment may be valued differently than claims involving shorter-term symptoms.
Settlement value may also depend on prescription history, diagnosis, treatment records, causation evidence, lost income, and available damages.
Any future Wegovy settlement would be evaluated based on the specific facts of each claim, not a fixed payout schedule.
Is There an Ozempic and Wegovy Class Action Lawsuit?
No, there is not a class action lawsuit for injuries and health problems associated with the use of Ozempic and Wegovy or other weight loss drugs.
Lawsuits for both Ozempic and Wegovy, as well as other semaglutide drugs, are being consolidated into a single federal court under a process known as multidistrict litigation (MDL).
The Judicial Panel on Multidistrict Litigation (JPML) certified the establishment of the Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability Litigation (MDL 3094) in the US District Court for the Eastern District of Pennsylvania.
The MDL involves personal injury actions stemming from GLP-1 RAs, including Novo Nordisk drugs Ozempic, Wegovy, and Rybelsus, and Eli Lilly drugs Trulicity and Mounjaro.
MDL and class action are separate and distinct legal processes.
The litigation provides an avenue for those with Wegovy and Ozempic Lawsuits to seek compensation in an organized and unified manner.
Within an MDL, your case remains individual and in the event of a settlement, a successful claim would be compensated according to the unique facts and circumstances of the case.
This is different from class action lawsuits, where claims are combined together into one legal action and the relief is generally determined on a classwide basis, subject to the structure of the class action.
What Drug Manufacturers are Named in the Ozempic and Wegovy Lawsuits?
The GLP-1 gastrointestinal injury MDL includes claims involving Novo Nordisk and Eli Lilly products.
Novo Nordisk manufactures Ozempic, Wegovy, and Rybelsus.
Eli Lilly manufactures Trulicity and Mounjaro.
Plaintiffs allege that these manufacturers failed to adequately warn about severe gastrointestinal risks, including gastroparesis, ileus, intestinal obstruction, pseudo-obstruction, and related injuries.
Do You Qualify for the Wegovy Lawsuit?
People who used Wegovy, or similar GLP-1 medications and later developed serious gastrointestinal injuries may have a potential claim, depending on diagnosis, timing, medical history, warning information, and other facts.
Lawsuits are now being filed on behalf of those who have developed severe gastroparesis and other serious injuries from taking Ozempic, Wegovy, and other GLP 1 RA medications.
If you were prescribed Wegovy or other semaglutide drugs and developed stomach paralysis, intestinal blockage, or other conditions affecting gastric emptying, you may be eligible to file a Wegovy Lawsuit.
Contact our lawyers today for a free consultation.
You can also use the chatbot on this page for a free case evaluation.
Lawyers will help their clients throughout the legal process, assisting them with gathering and retaining crucial evidence and assessing their damages.
Gathering Evidence for Wegovy Lawsuits
Evidence is important because a Wegovy claim must connect medication use, timing, diagnosis, injury severity, and damages.
It is essential that patients who have used these drugs retain any related medical documentation and further evidence to support their claims.
This is a part of the legal process you can begin on your own, but an experienced lawyer will help you gather and retain evidence.
Possible evidence in a Wegovy Lawsuit may include:
- Medical records: Documentation of diagnoses and treatments related to side effects.
- Prescription records: Evidence of Wegovy prescriptions and dosages.
- Diagnostic tests: Results of tests such as gastric emptying studies or endoscopies.
- Symptom diaries: Patient records detailing the onset and progression of symptoms.
- Expert testimony: Statements from medical professionals linking Wegovy use to health issues.
- Adverse event reports: Filed with the FDA or other regulatory bodies.
- Correspondence: Communications with healthcare providers regarding side effects.
- Product information: Labels, warnings, and marketing materials provided by Novo Nordisk.
- Research studies: Scientific literature and studies showing the risks associated with GLP-1 drugs.
- Witness statements: Testimonies from family members or caregivers about the impact on daily life.
This evidence can help build a strong case by demonstrating the direct connection between Wegovy use and the adverse health outcomes experienced by the patient
Damages in Wegovy Lawsuits
Damages are the losses allegedly caused by the injury. In Wegovy claims, damages depend on diagnosis, treatment, symptom duration, hospitalization, work impact, and long-term medical needs.
Your lawyer will help you to assess and calculate damages.
Possible damages in a Wegovy Lawsuit may include:
- Medical bills: Costs incurred for initial and ongoing treatments related to side effects.
- Future medical expenses: Anticipated costs for long-term medical care and treatments.
- Emotional distress: Psychological impact of the health issues and their treatment.
- Pain and suffering: Compensation for physical pain and discomfort experienced.
- Lost wages: Income lost due to inability to work while undergoing treatment.
- Loss of earning capacity: Reduction in future earning potential due to health complications.
- Loss of enjoyment of life: Impact on the ability to participate in and enjoy daily activities.
TorHoerman Law: Investigating the Wegovy Lawsuit
TorHoerman Law is reviewing claims involving Wegovy and other GLP-1 medications where users developed gastroparesis, intestinal obstruction, persistent vomiting, severe gastrointestinal complications, or NAION-related vision loss.
Our national law firm can evaluate prescription history, diagnosis, treatment records, hospitalization history, and the timeline between medication use and injury.
A Wegovy lawyer from TorHoerman Law can explain whether the facts may support a product liability claim and what evidence may be needed.
Contact TorHoerman Law today for a free case review.
Use the chat feature on this page to find out if you qualify for the Wegovy lawsuit.
